{'fraction_non_alphanumeric': 0.03881278538812785, 'fraction_numerical': 0.0045662100456621, 'mean_word_length': 5.455882352941177, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Rosigliazone Meta-Analysis

We read with interest the recent fixed-effects meta-analysis of the connection between rosiglitazone and both myocardial infarction and cardiac death and the lessons garnered from the Food and Drug Administration Advisory Meeting (1,2). We urge caution in data interpretation. Due to the diversity of the designs (eligibility, doses, duration of follow-up, concomitant medications), we view fixed-effects …